Core Viewpoint - Fuan Pharmaceutical's subsidiary, Qingyutang Pharmaceutical, has received a drug registration certificate from the National Medical Products Administration for "Cefotaxime Granules," which is indicated for various infections caused by sensitive bacteria [1] Company Summary - Fuan Pharmaceutical's subsidiary, Qingyutang, is now authorized to market Cefotaxime Granules, expanding its product portfolio [1] - The drug is suitable for treating superficial and deep skin infections, lymphangitis, chronic pyoderma, and various respiratory and urinary tract infections [1] - Currently, there are two companies, including Qingyutang, that have passed the consistency evaluation for this drug [1]

Core Viewpoint - Fuan Pharmaceutical's subsidiary, Qingyutang Pharmaceutical, has received a drug registration certificate from the National Medical Products Administration for "Cefotaxime Granules," which is indicated for various infections caused by sensitive bacteria [1] Company Summary - Fuan Pharmaceutical's subsidiary, Qingyutang, is now authorized to market Cefotaxime Granules, expanding its product portfolio [1] - The drug is suitable for treating superficial and deep skin infections, lymphangitis, chronic pyoderma, and various respiratory and urinary tract infections [1] - Currently, there are two companies, including Qingyutang, that have passed the consistency evaluation for this drug [1] Industry Summary - The approval of Cefotaxime Granules reflects ongoing regulatory support for new pharmaceutical products in the market [1] - The drug addresses a wide range of bacterial infections, indicating a potential growth area in the pharmaceutical industry [1]

Core Viewpoint - Fuan Pharmaceutical's subsidiary, Qingyutang, has received a drug registration certificate from the National Medical Products Administration for its product, Cefotolan Pivoxil Granules, indicating a significant regulatory milestone for the company [1] Group 1: Product Information - Cefotolan Pivoxil Granules are indicated for a variety of infections caused by sensitive bacteria, including superficial and deep skin infections, lymphangitis, chronic pyoderma, and secondary infections from trauma, burns, and surgical wounds [1] - The drug is also applicable for treating perianal abscesses, pharyngitis, laryngitis, tonsillitis, acute bronchitis, pneumonia, lung abscesses, chronic respiratory system diseases, otitis media, sinusitis, periodontitis, jaw inflammation, cystitis, pyelonephritis, scarlet fever, and whooping cough [1]

Core Viewpoint - Fuan Pharmaceutical (300194.SZ) has received a drug registration certificate from the National Medical Products Administration for its product, Cefotolan Pivoxil Granules, which is indicated for various infections caused by sensitive bacteria [1] Group 1: Company Developments - Fuan Pharmaceutical's wholly-owned subsidiary, Qingyutang Pharmaceutical Co., Ltd., has been granted a registration certificate for Cefotolan Pivoxil Granules [1] - The drug is suitable for treating superficial and deep skin infections, lymphangitis, chronic pyoderma, and other secondary infections [1] Group 2: Product Indications - Cefotolan Pivoxil Granules are indicated for a wide range of conditions including abscesses, pharyngitis, laryngitis, tonsillitis, acute bronchitis, pneumonia, and chronic respiratory diseases [1] - The product also addresses infections related to otitis media, sinusitis, periodontitis, jaw inflammation, cystitis, pyelonephritis, scarlet fever, and whooping cough [1]

Core Viewpoint - The announcement indicates that the wholly-owned subsidiary of Fu'an Pharmaceutical, Qingyutang, has received a drug registration certificate from the National Medical Products Administration for a new product, which is expected to enhance the company's product line and market competitiveness [1] Group 1: Product Registration - The drug name is Cefotaxime Sodium Granules, classified as a Category 4 chemical drug, with specifications of 50mg and 30mg [1] - The approval numbers for the drug are National Drug Approval Code H20256029 and H20256028 [1] - Currently, only two companies have passed the consistency evaluation or are deemed to have passed it for this drug [1] Group 2: Market Impact - The acquisition of the drug registration certificate will enrich the subsidiary's product line and improve its market competitiveness [1] - However, the production and sales situation of the product, as well as its specific impact on the company's performance, remain uncertain due to industry policies and market environment changes [1]

证券代码：300194 证券简称：福安药业 公告编号：2025-042 福安药业（集团）股份有限公司 关于子公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 二〇二五年十二月一日 | 药品名称 | 注册分类 | | 规格 | 药品上市许 可持有人 | 批准文号 | 审批结论 | | --- | --- | --- | --- | --- | --- | --- | | 头孢托仑匹酯 | 化药 4 | 类 | 50mg | 庆余堂 | 国药准字 H20256029 国药准字 | 经审查，本品符合药品注册的有关要 求，批准注册，发给药品注册证书。 | | 颗粒 | | | | | | | | | | | 30mg | | H20256028 | | 头孢托仑匹酯颗粒适用于敏感菌引起的浅表性皮肤感染、深部皮肤感染、淋 巴管及淋巴结炎、慢性脓皮病、外伤、烫伤以及手术创口等的继发性感染、肛周 脓肿、咽炎及喉炎、扁桃体炎、急性支气管炎、肺炎、肺脓肿、慢性呼吸系统病 变的继发性感染、中耳炎、鼻窦炎、牙周炎、颌炎、膀胱炎、肾盂肾炎、猩红热、 百日 ...

Group 1 - The company has applied for and obtained invention patents related to the crystal forms and preparation methods of its psychiatric drugs, Buprenorphine and Midazolam [2] - However, the company has not obtained any composition patents for these products [2]

Core Viewpoint - The company has a subsidiary that holds the production approval for Palivizumab injection, which is used for the treatment of influenza A and B. However, due to multiple factors such as centralized procurement policies and changes in the competitive market environment, the current sales volume of Palivizumab injection is very low, and it does not have a significant impact on the company's overall revenue and operating performance [1]. Group 1 - The company’s subsidiary possesses the production approval for Palivizumab injection [1] - Palivizumab injection is indicated for the treatment of influenza A and B [1] - Sales volume of Palivizumab injection is currently very low [1] Group 2 - The low sales volume is influenced by centralized procurement policies and market competition changes [1] - The current sales situation does not significantly affect the company's overall revenue [1] - The company's operating performance remains largely unaffected by the low sales of Palivizumab injection [1]

Core Viewpoint - Fu'an Pharmaceutical experienced a decline of 1.27% in stock price on November 17, with a trading volume of 117 million yuan, indicating a challenging market environment for the company [1] Financing Summary - On November 17, Fu'an Pharmaceutical had a financing buy-in amount of 12.45 million yuan and a financing repayment of 16.83 million yuan, resulting in a net financing outflow of 4.38 million yuan [1] - The total financing and securities balance for Fu'an Pharmaceutical as of November 17 is 403 million yuan, which accounts for 7.24% of its circulating market value, indicating a high level of financing compared to the past year [1] - The company had no short-selling activity on November 17, with a short-selling balance of 0 shares, reflecting a low level of short interest [1] Business Performance Summary - As of October 31, Fu'an Pharmaceutical had 39,200 shareholders, an increase of 0.72% from the previous period, while the average circulating shares per person decreased by 0.71% to 24,700 shares [2] - For the period from January to September 2025, Fu'an Pharmaceutical reported a revenue of 1.315 billion yuan, a year-on-year decrease of 34.08%, and a net profit attributable to shareholders of 166 million yuan, down 44.87% year-on-year [2] - Since its A-share listing, Fu'an Pharmaceutical has distributed a total of 688 million yuan in dividends, with 202 million yuan distributed over the past three years [2] Shareholding Summary - As of September 30, 2025, Hong Kong Central Clearing Limited was the eighth largest circulating shareholder of Fu'an Pharmaceutical, holding 4.9804 million shares, which is a decrease of 470,000 shares from the previous period [2]

11月14日，福安药业大宗交易成交100万股，成交额423万元，占当日总成交额的3.55%，成交价4.23 元，较市场收盘价4.74元折价10.76%。 | 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | 2025-11-14 | 300194 | 福安药业 | 4.23 | 100.00 | 423.00 中国中金财富证券 | 中国中金财富证券 | | | | | | | 有限公司海南分公 | 有限公司海南分公 | | | | | | | 司 | TG | ...